Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
| Revenue (Most Recent Fiscal Year) | $14.74B |
| Net Income (Most Recent Fiscal Year) | $-634.20M |
| PE Ratio (Current Year Earnings Estimate) | 3.93 |
| PE Ratio (Trailing 12 Months) | 3.56 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.72 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.67 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 1.73 |
| Pre-Tax Margin (Trailing 12 Months) | -27.39% |
| Net Margin (Trailing 12 Months) | -26.45% |
| Return on Equity (Trailing 12 Months) | 16.20% |
| Return on Assets (Trailing 12 Months) | 7.01% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.68 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.97 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.02 |
| Inventory Turnover (Trailing 12 Months) | 2.27 |
| Book Value per Share (Most Recent Fiscal Quarter) | $13.33 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.50 |
| Earnings per Share (Most Recent Fiscal Year) | $2.65 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.17 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 1.17B |
| Free Float | 1.17B |
| Market Capitalization | $10.36B |
| Average Volume (Last 20 Days) | 13.40M |
| Beta (Past 60 Months) | 0.89 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.13% |
| Percentage Held By Institutions (Latest 13F Reports) | 79.88% |
| Annual Dividend (Based on Last Quarter) | $0.48 |
| Dividend Yield (Based on Last Quarter) | 5.44% |